Stoli Catalysts.

Clean catalysis for more sustainable fine chemical production.

Stoli Catalysts designs and manufactures continuous flow processes that dramatically cut the manufacturing cost of fine and speciality chemicals such as fragrances, food supplements, cosmetics and intermediates for pharmaceuticals.

Technology & Products.

Stoli’s core technology is based on fixing catalysts to the inside walls of reactor tubing and other channel-based geometries and passing the multiphase gas and liquid components over the surfaces. In contrast, traditional batch processing mixes powdered catalysts in a pot with the other ingredients. Using continuous flow processing, StoliFlowTM systems are much more efficient than traditional batch processes and readily scalable. Production efficiencies in energy, labour, reaction time and waste deliver significant cost reductions and margin enhancement, as well as lower environmental impact. It has two patent applications at international stage.

The Market.

Stoli is targeting the $600bn fine chemicals market that includes perfumes, cosmetics, nutraceuticals and ingredients used to make pharmaceuticals. The near-term addressable market for StoliFlowTM products, system designs and services is approximately $800m. Its aim is to be the leader in sustainable, low-impact catalytic and enzymatic continuous flow production of fine and specialty chemicals. Longer-term target markets in enzymatic biosynthesis and biofuels are valued at over $2bn.

Business Model.

Stoli is developing a system design and licensing model with the first commercial-scale pilot plant to be delivered in H2.21. Additionally, it provides services in process and catalyst development, catalyst coatings, characterisation and proof-of-concept projects as a means to developing customer relationships. Sales to date are over £200,000. Customers include Airbus, Adisseo and SABIC.

Fundraising to july 2020.

The development of the pilot plant is being largely funded by a EUR1.2m (£1m) Horizon 2020 SME Instrument grant. It is raising up to £600,000 for match funding and to expand business development.

Team.

Chairman Quentin Compton-Bishop. Former CEO of Warwick Ventures, P2i and Rolatube Technology.
COO & CTO Dr Nikolay Cherkasov. Co-founder and lead inventor. Royal Academy of Engineering Enterprise Fellow.
CSO Prof. Evgeny Rebrov. Co-founder and Professor of Chemical Engineering at the University of Warwick.
Board Advisor Dr Fred Hancock. Former Technical Director for Johnson Matthey’s Global Catalysts & Chiral Technologies Business.

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.